Sign In
Buy MIST
$1.28
-0.0400 (-3.03%)
At Close: Jun 03, 2026
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
08:00am, Wednesday, 19'th Feb 2025
MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovat
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
08:00am, Tuesday, 11'th Feb 2025
MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
08:00am, Tuesday, 28'th Jan 2025
- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Tuesday, 07'th Jan 2025
MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity aw
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
10:56am, Tuesday, 19'th Nov 2024
Milestone Pharmaceuticals Inc. (MIST) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MIST's 50-day simple moving average broke out
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
09:03am, Tuesday, 12'th Nov 2024
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
08:00am, Wednesday, 04'th Sep 2024
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innova
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
04:17pm, Thursday, 08'th Aug 2024
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik
4 Stocks Under $5 To Buy Now
01:05pm, Thursday, 08'th Aug 2024
Are you looking for stocks to buy with low price tags?
MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovativ
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
08:00am, Friday, 31'st May 2024
MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Gl
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
07:00am, Wednesday, 29'th May 2024
MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat
Brokers Set Expectations for Milestone Pharmaceuticals Inc.’s Q2 2024 Earnings (NASDAQ:MIST)
01:38am, Monday, 20'th May 2024
Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Investment analysts at HC Wainwright boosted their Q2 2024 earnings per share (EPS) estimates for Milestone Pharmaceuticals in
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
01:01pm, Thursday, 16'th May 2024
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
